Dr. Agarwal’s Health Care Q1 FY27: dates, estimates 2026

What the Q1 FY27 results window looks like

Dr. Agarwal’s Health Care is approaching its Q1 FY27 (quarter ended June 30, 2026) results with two clear reference points: the company’s scheduled board meeting on August 4, 2026, and a market estimate band for revenue and profit. The information set flags an expected results window in July to August 2026, in line with the broader NSE and BSE results season for the June quarter. Alongside this, a separate line mentions an “upcoming earnings date” of May 21, 2026, but the dataset does not clarify what reporting period that refers to. Investors typically track such events closely because they set near-term expectations for financial disclosures and management commentary. The company is also slated to host an earnings and analyst call the same day as the board meeting. A trading window restriction is noted until 48 hours after the results announcement.

Board meeting on August 4, 2026 and what is on the agenda

The company’s Board of Directors is scheduled to meet on August 4, 2026 to consider and approve the unaudited standalone and consolidated financial results for the period. This is positioned as the formal trigger for the Q1 FY27 announcement. The same day is also reserved for an earnings and analyst conference call to discuss performance for the quarter ended June 30, 2026. According to the details provided, the call is scheduled from 5:30 PM to 6:30 PM IST. Such calls are typically used to share operating metrics, clarify quarter-on-quarter and year-on-year movements, and take analyst questions. No additional agenda items beyond the results approval are specified for this meeting in the provided text. The trading window is stated to remain closed until 48 hours after the announcement of results, aligned with the company’s code for prevention of insider trading.

Earnings call timing and dial-in details

The earnings call is scheduled for August 4, 2026 at 5:30 PM IST, with the time window listed as 5:30 PM to 6:30 PM IST. The dial-in numbers provided include India (+91 22 6280 1308 / +91 22 7115 8161), USA (18667462133), UK (08081011573), Canada (01180014243444), Australia (0080014243444), and Singapore (8001012045). This breadth suggests the company expects participation from domestic and overseas investors and analysts. The dataset does not include webcast links or passcodes. It also does not specify whether the call will include a prepared presentation. Still, the presence of a one-hour slot indicates a standard results discussion format.

Uniresearch estimate: Q1 FY27 revenue and PAT bands

The Uniresearch estimate for Dr. Agarwal’s Health Care’s Q1 FY27 revenue is ₹565-650 crore. The same estimate set gives a PAT range of ₹39-50 crore for Q1 FY27. The estimate is explicitly described as being based on a Q1 FY26 base of ₹501 crore revenue and ₹38 crore net profit. The table in the dataset presents year-on-year growth rates of +21.2% for revenue and +17.4% for PAT using that stated base period. The dataset also lists a 12-month target range of ₹551-613 as a Uniresearch estimate. Separately, the company is stated to be entering the Q1 FY27 results season trading at ₹474.

Quick-details snapshot from the dataset

A “Quick Details” block in the information set mentions the quarter as Q1 FY 2026-2027 and reiterates August 4, 2026 as the results date. It also lists a previous quarter revenue of ₹564 crore, previous quarter PAT of ₹50 crore, and a previous quarter EBITDA margin of 30.2%. These figures offer a quarter-to-quarter reference point, although the dataset does not specify whether they refer to consolidated or standalone numbers. The same quick block contains an unexplained “482.2” entry without context. Because no unit or label is provided for that number, it should be treated cautiously. The dataset also includes a “CMP” reference of ₹474 for Dr. Agarwal’s Health Care.

Corporate action watch: NCLT hearing on amalgamation

Beyond the quarterly results, the company has announced that the National Company Law Tribunal (NCLT), Chennai Bench, will hear its petition for a scheme of amalgamation with Dr. Agarwal’s Eye Hospital Limited on August 19, 2026. The dataset does not provide further detail on the structure of the scheme, swap ratios, or expected timelines beyond the hearing date. For investors, such proceedings can matter because they may affect reporting structure, consolidation, and governance arrangements. The next concrete milestone in the provided information is the August 19 hearing.

Operating expansion and FY26 performance pointers cited

The dataset states that the company crossed ₹2,000 crore in revenue for the first time and reported total income of ₹2,125 crore for FY26, a year-on-year rise of 20.9% from ₹1,757 crore in FY25. It also notes EBITDA increased 22.2% year-on-year, with margins improving by 31 basis points to 28.9%. On network expansion, the information set mentions 19 new facilities were opened in Q4 and that the company plans to launch 60 additional facilities in FY27. Another operational note says the company plans to launch a new CMS by October 1, 2026, contingent upon approvals. A cash flow point is also included: FY26 cash outflow was roughly ₹85 crore, with FY27 expected cash outflow in the ₹60-65 crore range.

Additional quarterly operational metrics mentioned

The dataset includes a set of quarterly operating indicators such as surgeries performed and quarterly income snapshots. It states that 81,002 surgeries were performed in Q3 FY26 (11.2% year-on-year growth), and 78,399 surgeries were performed in Q2 FY26 (13.3% year-on-year growth). It also lists quarterly income and profitability items: in one section, EBITDA of ₹155 crore with EBITDA margins of 28.6% and PAT of ₹44 crore with PAT margins of 8.1% are referenced (the quarter is not explicitly labeled in that specific bullet list). Revenue from operations figures of ₹499 crore and ₹530 crore are also cited for different quarters, with India revenue from operations at ₹480 crore in the same set of bullets. Because these metrics are presented as separate bullets without a single consolidated table, readers should align them to the associated quarter labels shown alongside them in the dataset.

Key numbers table: dates, estimates, and reference points

Market impact and what investors are likely to track

With the results and call set for August 4, the near-term market focus is likely to stay on whether reported revenue and PAT land within the ₹565-650 crore and ₹39-50 crore bands cited by Uniresearch. The previous-quarter reference points in the dataset - revenue of ₹564 crore, PAT of ₹50 crore, and EBITDA margin of 30.2% - may also shape how investors compare sequential performance. The 12-month target range of ₹551-613 is presented as an estimate, and the stock’s stated CMP of ₹474 provides a current reference level from the same information set. Separately, the NCLT hearing on August 19 introduces a corporate structure event investors may monitor alongside earnings. The trading window closure until 48 hours after results is also highlighted as a compliance item that can affect near-term insider transactions.

Conclusion: the next two dates that matter

Dr. Agarwal’s Health Care has two defined milestones in August 2026: the August 4 board meeting and earnings call for Q1 FY27 results, and the August 19 NCLT hearing related to the amalgamation petition. The estimate set cited in the dataset places Q1 FY27 revenue at ₹565-650 crore and PAT at ₹39-50 crore, benchmarked to Q1 FY26 revenue of ₹501 crore and PAT of ₹38 crore. Investors looking for clarity will likely focus on the reported numbers, management commentary during the 5:30 PM IST call, and any updates on the amalgamation process following the tribunal hearing.